KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Abbott Laboratories (ABT) Non Operating Income (2016 - 2026)

Abbott Laboratories' Non Operating Income history spans 18 years, with the latest figure at $159.0 million for Q1 2026.

  • On a quarterly basis, Non Operating Income rose 25.2% to $159.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $580.0 million, a 47.96% increase, with the full-year FY2025 number at $548.0 million, up 45.74% from a year prior.
  • Non Operating Income hit $159.0 million in Q1 2026 for Abbott Laboratories, up from $134.0 million in the prior quarter.
  • Over the last five years, Non Operating Income for ABT hit a ceiling of $176.0 million in Q2 2023 and a floor of -$10.0 million in Q2 2024.
  • Historically, Non Operating Income has averaged $110.8 million across 5 years, with a median of $111.0 million in 2023.
  • Biggest five-year swings in Non Operating Income: plummeted 105.68% in 2024 and later soared 1470.0% in 2025.
  • Tracing ABT's Non Operating Income over 5 years: stood at $68.0 million in 2022, then soared by 60.29% to $109.0 million in 2023, then soared by 41.28% to $154.0 million in 2024, then decreased by 12.99% to $134.0 million in 2025, then rose by 18.66% to $159.0 million in 2026.
  • Business Quant data shows Non Operating Income for ABT at $159.0 million in Q1 2026, $134.0 million in Q4 2025, and $150.0 million in Q3 2025.